VIVUS Inc

VIVUS — J.P. Morgan Healthcare Conference 2013

23 slides from VIVUS's conference presentation, Jan 7, 2013

  1. Slide 1: J.P. Morgan Healthcare Conference 2013: Innovative Therapies, Novel Products

    Slide 1: J.P. Morgan Healthcare Conference 2013: Innovative Therapies, Novel Products

    J.P. Morgan Healthcare Conference 2013 January 7-9, 2013 - San Francisco, California INNOVATIVE THERAPIES NOVEL PRODUCTS ©2013 VIVUS Inc. All rights reserved | www.vivus.com

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect,"

  3. Slide 3: Innovative Therapies; Novel Products

    Slide 3: Innovative Therapies; Novel Products

    INNOVATIVE THERAPIES; NOVEL PRODUCTS Two newly approved products in high potential markets: Qsymia™ for chronic weight management Stendra™ for erectile dysfunction ©2013 VIVUS Inc. All rights reserved | www.vivus.com 2

  4. Slide 4: Qsymia Prescribing Information

    Slide 4: Qsymia Prescribing Information

    QSYMIA PRESCRIBING INFORMATION ©2013 VIVUS Inc. All rights reserved | www.vivus.com 3

  5. Slide 5: Transforming the Obesity Market

    Slide 5: Transforming the Obesity Market

    TRANSFORMING THE OBESITY MARKET 4 ©2013 VIVUS Inc. All rights reserved | www.vivus.com 4

  6. Slide 6: Building the Qsymia Franchise

    Slide 6: Building the Qsymia Franchise

    Educate Physicians Broaden Reimbursement Expand to Retail Pharmacies Expand PCP Reach & DTC BUILDING THE QSYMIA FRANCHISE ©2013 VIVUS Inc. All rights reserved | www.vivus.com 5 Launch Time

  7. Slide 7: Qsymia Prescriptions Launch to Date

    Slide 7: Qsymia Prescriptions Launch to Date

    QSYMIA PRESCRIPTIONS LAUNCH* TO DATE ©2013 VIVUS Inc. All rights reserved | www.vivus.com 6 Rolling Four Week TRx’s (000s) 0 2 4 6 8 10 12 14 0.6 5.4 7.7 13.0 3Q2012 10/26** 11/23 12/21 * Mid-Sep-2012; ** Adjusted Source: Vivus Data Warehouse - 21-Dec-2012 | Reported from 3rd parties and may be subj

  8. Slide 8: Qsymia Cumulative Total Patients

    Slide 8: Qsymia Cumulative Total Patients

    QSYMIA CUMULATIVE TOTAL PATIENTS ©2013 VIVUS Inc. All rights reserved | www.vivus.com 7 Cumulative Patients (000s) 0 2 4 6 8 10 12 14 16 9/21 9/28 10/5 10/12 10/19 10/26 11/02 11/09 11/16 11/23 11/30 12/7 12/14 12/21 14.5 Source: Vivus Data Warehouse - 21-Dec-2012 | Reported from 3rd parties and may

  9. Slide 9: Major PBM Validates Qsymia

    Slide 9: Major PBM Validates Qsymia

    MAJOR PBM VALIDATES QSYMIA Qsymia now on ESI National Preferred Formulary Among the largest Pharmacy Benefit Managers (PBM) Manages pharmacy benefit for 26.3MM lives U.S.* Tier 3; Prior Authorization Co-pay: ~$50 - $60 ©2013 VIVUS Inc. All rights reserved | www.vivus.com 8 *HealthLeaders InterStudy

  10. Slide 10: Adult Obesity - A Costly Epidemic

    Slide 10: Adult Obesity - A Costly Epidemic

    1 Gonzalez, et al. NEJM 2010; 363:2211-9. 2 Flegal KM, et al. JAMA 2007;298:2028-2037 3 Logue, et al., Heart 2011:doi:10.1136/hrt 2010.211201 4 CDC National Center for Health Statistics. Health, United States, 2011 5 OECD Health at a Glance, December 2010, WHO The Challenge of Obesity in the WHO Eur

  11. Slide 11: Qsymia Magnitude of Effect

    Slide 11: Qsymia Magnitude of Effect

    ©2013 VIVUS Inc. All rights reserved | www.vivus.com QSYMIA MAGNITUDE OF EFFECT PIVOTAL 1-YEAR STUDIES: WEIGHT LOSS OVER TIME (OBSERVED DATA) 10 Study 1 (EQUIP) Study 2 (CONQUER) Time (Week) Time (Week) 56 ITT-LOCF 56 ITT-LOCF All observed data; *p<0.0001 vs placebo; ‡p<0.0001 vs. Qsymia Mid or Low

  12. Slide 12: Qsymia Consistency of Effect

    Slide 12: Qsymia Consistency of Effect

    QSYMIA CONSISTENCY OF EFFECT ©2013 VIVUS Inc. All rights reserved | www.vivus.com 11 *Dvorak, R., Peterson, C., Day, W. Application of Proposed Treatment Algorithm (PTA) Improves the Benefit/Risk Profile of Phentermine Plus Extended-Release Topiramate (PHEN/TPM ER) Presented at The Obesity Society 3

  13. Slide 13: Building the Qsymia Franchise

    Slide 13: Building the Qsymia Franchise

    Educate Physicians Broaden Reimbursement Expand to Retail Pharmacies Expand PCP Reach & DTC BUILDING THE QSYMIA FRANCHISE ©2013 VIVUS Inc. All rights reserved | www.vivus.com 12 Launch Time

  14. Slide 14: Qsymia Tactical Accomplishments

    Slide 14: Qsymia Tactical Accomplishments

    QSYMIA TACTICAL ACCOMPLISHMENTS 13 Educate Prescribers Stimulate Patient Trial Improve Coverage of Obesity Expand to Retail Pharmacies Patient Awareness CME attendees: ~6,600 Details since launch: ~50,000 Qsymia Get Started! Program (14 Days Free) Express Scripts (ESI) adds Qsymia as Standard Pharma

  15. Slide 15: Qsymia: Expansion to Retail

    Slide 15: Qsymia: Expansion to Retail

    QSYMIA: EXPANSION TO RETAIL REMS Modification Submission to FDA: “...we request that you submit a REMS modification that will facilitate dispensing through a broader range of pharmacies...” (NDA Approval Letter) Submitted Oct-2012; six-month review expected GOAL: Expand from mail order-only to inclu

  16. Slide 16: Qsymia Certified Pharmacies

    Slide 16: Qsymia Certified Pharmacies

    Qsymia Home Delivery Network ©2013 VIVUS Inc. All rights reserved | www.vivus.com 15 Walmart Pharmacy QSYMIA CERTIFIED PHARMACIES Kaiser Permanente (For Kaiser members only)

  17. Slide 17: Expanding the Qsymia Prescriber Base

    Slide 17: Expanding the Qsymia Prescriber Base

    EXPANDING THE QSYMIA PRESCRIBER BASE ©2013 VIVUS Inc. All rights reserved | www.vivus.com 16 Source: Vivus Data Warehouse - 21-Dec-2012 | Reported from 3rd parties and may be subject to adjustment

  18. Slide 18: Qsymia Prescribers by Specialty

    Slide 18: Qsymia Prescribers by Specialty

    QSYMIA PRESCRIBERS BY SPECIALTY ©2013 VIVUS Inc. All rights reserved | www.vivus.com 17 Cumulative Unique Prescribers (000s) 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 9/21 9/28 10/5 10/12 10/19 10/26 11/02 11/09 11/16 11/23 11/30 12/7 12/14 12/21 2012 Source: Vivus Data Warehouse - 21-Dec-2012, All Pr

  19. Slide 19: Qsymia: A Vision for the Brand

    Slide 19: Qsymia: A Vision for the Brand

    QSYMIA: A VISION FOR THE BRAND Obesity treatment becomes mainstream medicine Widely accepted by primary care physicians Broadly reimbursed Substantial consumer awareness & acceptance Qsymia will become the product of choice Double digit efficacy Well tolerated Improvements in co-morbidities ©2013 VI

  20. Slide 20: Stendra Prescribing Information

    Slide 20: Stendra Prescribing Information

    STENDRA™ PRESCRIBING INFORMATION ©2013 VIVUS Inc. All rights reserved | www.vivus.com 19

  21. Slide 21: Stendra

    Slide 21: Stendra

    STENDRA™ Highly selective PDE5i with rapid onset EMA decision anticipated 1Q2013 Opportunity to commercialize in the US, EU and ROW Partnering discussions underway ©2013 VIVUS Inc. All rights reserved | www.vivus.com 20

  22. Slide 22: VIVUS Investment Highlights

    Slide 22: VIVUS Investment Highlights

    VIVUS INVESTMENT HIGHLIGHTS Two FDA approved products Making significant progress in building the Qsymia brand Educating physicians Expanding reimbursement Working to expand distribution Growing Qsymia prescriptions ©2013 VIVUS Inc. All rights reserved | www.vivus.com 21

  23. Slide 23: Innovative Therapies Novel Products

    Slide 23: Innovative Therapies Novel Products

    INNOVATIVE THERAPIES NOVEL PRODUCTS ©2013 VIVUS Inc. All rights reserved | www.vivus.com

Source: SEC EDGAR · 8-K filed Jan 7, 2013

More decks from VIVUS Inc